Article
Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic…
Cancer Management and Research · 2020 · Qian W, Wang L, Li P, Hu Y, Wang Q, Yi K, Wu M, Xu Y, Song J, Chen P, Zhang H, Ma J, Xie Y
Key facts
| Title | Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients |
|---|---|
| First author | Qian W, Wang L, Li P, Hu Y, Wang Q, Yi K, Wu M, Xu Y, Song J, Chen P, Zhang H, Ma J, Xie Y |
| Journal | Cancer Management and Research |
| Published | Jan 20, 2020 |
| DOI | 10.2147/CMAR.S212455 |
| Devices mentioned | 212455 |
At a glance
- 1–9 FDA submissions mentioned
- None Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1